Published in Osteoporos Int on July 24, 2004
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ (2009) 2.90
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J (2007) 1.51
At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int (2006) 1.36
Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos Int (2006) 1.21
Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int (2008) 1.06
An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int (2006) 0.96
A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int (2013) 0.94
Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int (2013) 0.92
Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int (2012) 0.90
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int (2009) 0.86
Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int (2005) 0.86
Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int (2010) 0.84
The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskelet Disord (2012) 0.84
Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int (2005) 0.82
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health (2007) 0.79
The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int (2009) 0.79
Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. Breast Care (Basel) (2009) 0.79
Cost-effectiveness of Pharmaceutical Interventions to Prevent Osteoporotic Fractures in Postmenopausal Women with Osteopenia. J Bone Metab (2016) 0.75
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Br J Cancer (2009) 0.75
Sequential use of antiresorptives in younger women. Osteoporos Int (2013) 0.75
Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int (2013) 0.75
Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ (1998) 8.27
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29
Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet (1999) 7.14
Population-based study of survival after osteoporotic fractures. Am J Epidemiol (1993) 4.71
The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med (1993) 4.04
NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ (2001) 4.01
Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med (1997) 3.96
Risk of mortality following clinical fractures. Osteoporos Int (2000) 3.76
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int (2000) 2.99
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med (2000) 2.77
The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int (1998) 2.77
Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA (1996) 2.53
Bone-density measurement. Lancet (1992) 2.38
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab (2000) 2.34
Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ (2000) 2.27
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone (2000) 1.89
The risk and burden of vertebral fractures in Sweden. Osteoporos Int (2003) 1.74
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ (1998) 1.48
Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res (2003) 1.39
Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int (2000) 1.35
Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone (2002) 1.30
Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess (2002) 1.26
Colles' fracture of the wrist as an indicator of underlying osteoporosis in postmenopausal women: a prospective study of bone mineral density and bone turnover rate. Osteoporos Int (1998) 1.14
Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis. J Bone Miner Res (2001) 1.08
A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int (2002) 1.06
Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med (1997) 1.04
Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics (2003) 1.02
A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics (1996) 1.02
Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int (1999) 0.99
Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone (2002) 0.91
The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics (1995) 0.91
Intervention thresholds for osteoporosis. Bone (2002) 0.90
Hormone replacement therapy in a risk-benefit perspective. Maturitas (1996) 0.88
Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int (2001) 0.85
Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int (2004) 0.85
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics (2004) 0.84
A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care (1999) 0.79
Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int (2002) 0.78
A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Med Inform (Lond) (1992) 0.77
Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs. Health Care Manag Sci (2001) 0.75
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
The economic cost of brain disorders in Europe. Eur J Neurol (2012) 3.53
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
A prospective randomised trial of internal fixation versus arthroplasty for displaced fractures of the neck of the femur. Functional outcome for 450 patients at two years. J Bone Joint Surg Br (2002) 3.40
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int (2001) 3.23
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Exercise during growth and bone mineral density and fractures in old age. Lancet (2000) 3.06
Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int (2000) 2.99
Economic evaluation of pharmaceuticals: a European perspective. Pharmacoeconomics (1993) 2.96
An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int (2001) 2.94
The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int (2001) 2.81
The prevalence of urinary incontinence in women in four European countries. BJU Int (2004) 2.75
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
The components of excess mortality after hip fracture. Bone (2003) 2.63
Validity of self-report of fractures: results from a prospective study in men and women across Europe. EPOS Study Group. European Prospective Osteoporosis Study Group. Osteoporos Int (2000) 2.52
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest (1987) 2.40
Projecting the need for hip replacement over the next three decades: influence of changing demography and threshold for surgery. Ann Rheum Dis (1999) 2.36
SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation (1996) 2.23
Pitfalls in the external validation of FRAX. Osteoporos Int (2011) 2.21
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos (2011) 2.14
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol (2008) 2.12
Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int (2004) 2.11
Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04
Conservative treatment of acute low-back pain. A prospective randomized trial: McKenzie method of treatment versus patient education in "mini back school". Spine (Phila Pa 1976) (1990) 2.01
Current trends in the use of pharmacoeconomics and outcomes research in europe. Value Health (2006) 1.96
Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone (2000) 1.89
Long-term follow-up of patients with untreated scoliosis. A study of mortality, causes of death, and symptoms. Spine (Phila Pa 1976) (1992) 1.88
Conversion factor instability in international comparisons of health care expenditure. J Health Econ (1991) 1.83
The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int (1992) 1.81
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med (1997) 1.79
Economic evaluation in health care: is there a role for cost-benefit analysis? Health Policy (1991) 1.77
Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int (2008) 1.77
Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (1998) 1.76
Are the findings in the Swedish National Total Hip Arthroplasty Register valid? A comparison between the Swedish National Total Hip Arthroplasty Register, the National Discharge Register, and the National Death Register. J Arthroplasty (2000) 1.75
The risk and burden of vertebral fractures in Sweden. Osteoporos Int (2003) 1.74
Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int (2003) 1.74
Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke (2001) 1.73
Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos (2013) 1.72
Funding of headache research in Europe. Cephalalgia (2007) 1.71
A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int (2002) 1.70
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Outcome measurement in economic evaluation. Health Econ (1997) 1.69
A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas (1995) 1.67
Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int J Clin Pract (2009) 1.66
Effect of Streptococcus pneumoniae on human respiratory epithelium in vitro. Infect Immun (1989) 1.64
Surgical versus non-surgical treatment of ligamentous injuries following dislocation of the elbow joint. A prospective randomized study. J Bone Joint Surg Am (1987) 1.63
Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med (2000) 1.63
Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry (2006) 1.61
Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum (1999) 1.61
An econometric analysis of health care expenditure: a cross-section study of the OECD countries. J Health Econ (1992) 1.60
Bone mineral density predicts non-spine fractures in very elderly women. Study of Osteoporotic Fractures Research Group. Osteoporos Int (1994) 1.60
Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporos Int (1999) 1.59
Glycosylated haemoglobin in the diagnosis of diabetes mellitus in elderly people. Age Ageing (1992) 1.58
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
Cancer risk after hip replacement with metal implants: a population-based cohort study in Sweden. J Natl Cancer Inst (1995) 1.53
Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int (1993) 1.53
Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis (2000) 1.53
Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol (1999) 1.51
Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs. Int J Clin Pract (2007) 1.50
Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ (1998) 1.48
Incidence of hip fractures in Malmö, Sweden, 1992-1995. A trend-break. Acta Orthop Scand (1999) 1.48
Increasing age-adjusted risk of fragility fractures: a sign of increasing osteoporosis in successive generations? Calcif Tissue Int (1989) 1.48
The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int (1994) 1.46
The excess mortality due to periprosthetic femur fracture. A study from the Swedish national hip arthroplasty register. Bone (2007) 1.46
Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2003) 1.45
Risk factors for fragility fracture in middle age. A prospective population-based study of 33,000 men and women. Osteoporos Int (2006) 1.44
Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporos Int (1997) 1.43
Crystal structure of ferrochelatase: the terminal enzyme in heme biosynthesis. Structure (1997) 1.42
Help-seeking behaviour and associated factors among women with urinary incontinence in France, Germany, Spain and the United Kingdom. Eur Urol (2004) 1.42
The burden of hospitalised fractures in Sweden. Osteoporos Int (2004) 1.41
Long-term sequelae of simple dislocation of the elbow. J Bone Joint Surg Am (1984) 1.41